Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population.
FibroScan
MASLD
glomerular filtration rate
hepatic fibrosis
kidney disease
steatotic liver disease
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
18
09
2023
revised:
27
10
2023
accepted:
29
10
2023
medline:
15
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
Glomerular hyperfiltration (GH) is an increase in the glomerular filtration rate, possibly progressing to chronic kidney disease (CKD). Metabolic-associated steatotic liver disease (MASLD) is linked to an increased risk of CKD, especially if fibrosis is present; however, the association between GH and MASLD has not been explored. To evaluate GH prevalence in MASLD and its possible correlation with liver fibrosis. 772 consecutive patients with ultrasound MASLD (mean age 47.3 ± 8.9 years, 67.1% males) were enrolled. GH was defined as estimated glomerular filtration rate (eGFR) greater than the upper quartile of values in the cohort. Liver stiffness measurement (LSM) by FibroScan ≥ 7.2 kPa suggested liver fibrosis. GH was present in 20% of patients, liver fibrosis in 30%. In total, 53.4% of the cohort was obese, 40.9% hypertensive, 36.3% diabetic and 70.8% dyslipidaemic. GH patients compared to non-GH were significantly younger (38.4 ± 8.3 vs. 49.5 ± 7.7,
Identifiants
pubmed: 37958820
pii: ijms242115837
doi: 10.3390/ijms242115837
pmc: PMC10649990
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero della Salute
ID : Ricerca Finalizzata RF-2021-12374481
Références
Atherosclerosis. 2019 Dec;291:124-126
pubmed: 31668350
Front Med (Lausanne). 2022 Jul 14;9:957437
pubmed: 35911392
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
PLoS One. 2020 Jan 28;15(1):e0228361
pubmed: 31990949
PLoS Med. 2014 Jul 22;11(7):e1001680
pubmed: 25050550
Metabolism. 2018 Feb;79:64-76
pubmed: 29137912
J Pers Med. 2022 Jul 14;12(7):
pubmed: 35887639
J Am Soc Nephrol. 2015 Jun;26(6):1426-33
pubmed: 25343954
Hepatology. 2015 May;61(5):1547-54
pubmed: 25125077
Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):2070-2077
pubmed: 32699074
BMC Nephrol. 2013 Dec 05;14:271
pubmed: 24304464
Am J Physiol Renal Physiol. 2000 May;278(5):F817-22
pubmed: 10807594
Clin Diabetes. 2020 Jan;38(1):10-38
pubmed: 31975748
Int J Mol Sci. 2021 Feb 26;22(5):
pubmed: 33652942
World J Gastroenterol. 2019 Oct 28;25(40):6053-6062
pubmed: 31686762
J Clin Med. 2021 Apr 16;10(8):
pubmed: 33923418
Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3
pubmed: 2520314
J Pediatr. 2020 Jul;222:127-133
pubmed: 32381466
Epidemiol Health. 2021;43:e2021001
pubmed: 33445827
Aliment Pharmacol Ther. 2019 May;49(9):1214-1222
pubmed: 30882933
Gut. 2006 Mar;55(3):403-8
pubmed: 16020491
Ann Hepatol. 2023 Jun 24;29(1):101133
pubmed: 37364816
Kidney Int. 2018 Jan;93(1):195-203
pubmed: 28935213
Gut. 2022 Jan;71(1):156-162
pubmed: 33303564
Clin J Am Soc Nephrol. 2010 Jun;5(6):1003-9
pubmed: 20299365
Nat Rev Nephrol. 2022 Jul;18(7):435-451
pubmed: 35365815
Am J Kidney Dis. 2014 Oct;64(4):638-52
pubmed: 25085644
Pediatr Radiol. 2017 Feb;47(2):221-226
pubmed: 27812743
G Ital Cardiol (Rome). 2018 Nov;19(11 Suppl 1):3S-73S
pubmed: 30520455
Int J Mol Sci. 2022 Jun 23;23(13):
pubmed: 35806010
J Am Soc Nephrol. 2006 Aug;17(8):2120-6
pubmed: 16825331
PLoS One. 2017 Apr 19;12(4):e0175298
pubmed: 28423054
Diagnostics (Basel). 2022 Sep 22;12(10):
pubmed: 36291976
Diabetes Care. 2023 Apr 1;46(4):845-853
pubmed: 36787983
Diabetes Res Clin Pract. 2023 Jul;201:110729
pubmed: 37230296
Am J Kidney Dis. 2004 Feb;43(2):396; author reply 396-7
pubmed: 14750109